menu
    • menu

    Company profile for UTILITY therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections.UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two Eu...
    UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections.UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    UTILITY therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Ely, Cambridgeshire
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://utilitytherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/utilitytherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alembic Pharma Acquires Utility Therapeutics for $12 Million
    Alembic Pharma Acquires Utility Therapeutics for $12 Million

    05 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/alembic-pharmaceuticals-acquires-utility-therapeutics-for-12-million-to-strengthen-us-footprint-17345

    INDPHARMAPOST
    05 Jul 2025
    Share Share
    FDA Concerns Over Iterum's UTI Drug And Antimicrobial Resistance
    FDA Concerns Over Iterum's UTI Drug And Antimicrobial Resistance

    06 Sep 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fda-concerned-iterums-urinary-tract-infection-drug-could-cause-antimicrobial-resistance

    FIERCE BIOTECH
    06 Sep 2024
    Share Share
    FDA greenlights Pivya as first new uncomplicated UTI antibiotic in 20 years
    FDA greenlights Pivya as first new uncomplicated UTI antibiotic in 20 years

    25 Apr 2024

    // FDA

    https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections#:~:text=Today%2C%20the%20U.S.%20Food%20and,Proteus%20mirabilis%20and%20Staphylococcus%20saprophyticus.

    FDA
    25 Apr 2024
    Share Share
    UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund
    UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund

    17 Jan 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=825382&lang=en

    ACCESSWIRE
    17 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search